Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-08-28 Interim / Quarterly Rep…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
2025 INTERIM REPORT
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled '2025 Interim Report' and contains comprehensive financial sections including 'Unaudited Condensed Consolidated Balance Sheets', 'Statements of Operations', 'Cash Flows', and 'Management Discussion and Analysis'. It covers a period shorter than a full fiscal year (six months ended June 30, 2025). It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis. H2 2025
2025-08-28 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'Interim Report' for Zai Lab Limited for the six months ended June 30, 2025. It contains detailed financial statements (balance sheets, statements of operations, cash flows), management discussion and analysis (MD&A), and corporate governance information. Although it begins with an 'Interim Results Announcement' header, the document text explicitly includes the full content of the 2025 interim report, including financial tables and notes, which qualifies it as an Interim/Quarterly Report (IR) rather than just an announcement. H1 2025
2025-08-26 English
GRANT OF RESTRICTED SHARE UNITS
Share Issue/Capital Change Classification · 88% confidence The document is an announcement of the grant of restricted share units (RSUs) under the company’s equity incentive plan. It details the number of units granted, vesting schedules, share pricing, and related terms under Hong Kong Listing Rules. This constitutes a notice of a new share issuance/capital change rather than a management discussion, earnings release, dividend notice, or other category. Therefore it best fits the “Share Issue/Capital Change” (SHA) classification.
2025-08-13 English
NOTICE OF AUDIT COMMITTEE ACTION
Report Publication Announcement Classification · 85% confidence The document is a short announcement (2,339 characters) titled “Notice of Audit Committee Action” stating the date when the Audit Committee will consider and approve interim results and arrange publication. It does not contain the financial results themselves, but rather announces the timing of a committee meeting and subsequent publication of the interim report. This fits the definition of a Report Publication Announcement (RPA), which covers notices about the timing or release of company reports.
2025-08-13 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 85% confidence The document is a directive “Next Day Disclosure Return” under HKEX rules detailing changes in issued shares (new share issuance to satisfy share awards). It is an announcement of share capital changes (increase in issued shares), fitting the definition of a Share Issue/Capital Change rather than a full report or earnings release. Therefore it should be classified as SHA (Share Issue/Capital Change).
2025-08-12 English
OVERSEAS REGULATORY ANNOUNCEMENT - FORM 10-Q
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q, which is a quarterly report filed with the SEC. It contains comprehensive financial statements, management's discussion and analysis (MD&A), and other required disclosures for the period ended June 30, 2025. Although it is introduced by a short 'Overseas Regulatory Announcement' cover page, the bulk of the document is the actual 10-Q report itself, which qualifies as an Interim/Quarterly Report (IR) under the provided definitions. Q2 2025
2025-08-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.